To determine whether istradefylline, an FDA-approved selective A2AR antagonist for PD, would prevent the previously reported adenosine-induced post-hypoxia synaptic potentiation (APSP) in hypoxia/reperfusion [24], hippocampal slices were subjected to 20 min of hypoxia followed by 45 min of normoxic perfusion as described before [23,24]. The gene discussed is ADORA2A; the disease is Parkinson disease.